联合检测胸腔积液和血清肿瘤标记物VEGF、TPS、CEA的临床价值探讨

摘要

目的:探讨联合检测肿瘤标记物组织多肽抗原(TPS)、血管内皮生长因子(VEGF)、癌胚抗原(CEA)水平在良、恶性胸腔积液中鉴别诊断的临床意义.方法:采集62例恶性胸腔积液和35例良性胸腔积液的胸腔积液标本,及对应病人的血清样本,用酶联免疫法(ELISA)测定血清及胸腔积液中的VEGF、TPS的含量；CEA的测定采用化学发光免疫法.结果:恶性组病人胸腔积液和血清肿瘤指标值均明显高于良性组,且胸腔积液中的含量更高；联合检测3种肿瘤标记物的敏感性、特异性和准确性更高,均明显高于测定任何一种肿瘤标记物.结论:联合检测胸腔积液或血清VEGF、TPS和CEA含量可以提高恶性胸腔积液的诊断率,对胸腔积液的良、恶性鉴别具有较好的临床价值.%Objective: To study the clinical value of combined determination of vascular endothelialgrowth factor (VEGF), tissue polypeptide-specific antigen (TPS) and carcinoembryonic antigen (CEA). Methods: Collected the 97 paitents examples of pleural effusion and serum, measured the level of VEGF and TPS by ELISA methods and CEA was tested by chemiluminescence. Results: Both in pleural effusion and serum, the level of VEGF, TPS and CEA of patients with malignant tumor were higher than those in nonmalignant disease, the difference of the former was more obviously. The sensitivity., specificity and accuracy of combine testing three markers were higher than testing only one. Conclution: The Clinical value of combine detection of VEGF, TPS and CEA in serum and pleural effusion is better.